CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) today announced that the French regulatory agency for medical products, the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS) has granted regulatory approval in France for use of plasma treated with the INTERCEPT Blood System, subject to official journal publication. Before the plasma system can be launched broadly in France, reimbursement pricing also needs to be established.
